You just read:

Rock Creek Pharmaceuticals Announces Inhibition of STAT 3 Activation, A Key Marker of Inflammation, In Phase I Clinical Trial in Europe

News provided by

Rock Creek Pharmaceuticals, Inc.

03 Feb, 2016, 13:45 GMT